Share on LinkedInShare on LinkedIn

ARTICLE · 12 SEPTEMBER 2018

Federal Circuit Patent Updates - September 2018

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

Taranto, J. Affirming district court judgment that claims directed to dosing of drug to treat multiple sclerosis were obvious.

United StatesIntellectual Property

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. (No. 2017-2078, -2134, 9/10/18) (Newman, Dyk, Taranto)

Taranto, J. Affirming district court judgment that claims directed to dosing of drug to treat multiple sclerosis were obvious. The prior art did not teach away and would have led to a reasonable expectation that the claimed dosing method would be efficacious. Pharmacokinetic limitations of the claims were inherent in the claimed method. The district court did not clearly err in discounting evidence of commercial success in light of a blocking patent. Newman, J., dissented.

A full version of the text is available in PDF form.

University of California v. Broad Institute, Inc. (No. 2017-1907, 9/10/18) (Prost, Schall, Moore)

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from